Royalty Pharma Reports Q4 and Full Year 2025 Results
Rhea-AI Summary
Royalty Pharma (Nasdaq: RPRX) reported Q4 2025 Portfolio Receipts of $874 million and full‑year 2025 Portfolio Receipts of $3,254 million, growth of 18% Q4 and 16% FY. Net cash provided by operations was $827 million in Q4 and $2,490 million for FY 2025.
The company deployed $2.6 billion on royalty transactions in 2025, repurchased 37 million Class A shares for $1.2 billion, and raised the quarterly dividend 7% to $0.235 per share. Full‑year 2026 Portfolio Receipts guidance is $3,275M–$3,425M.
Positive
- Portfolio Receipts +16% YoY to $3,254M for 2025
- Royalty Receipts +13% YoY to $3,127M for 2025
- Capital Deployment of $2.6B in 2025 adding royalties on nine therapies
- Share repurchases of $1.2B (37 million Class A shares) in 2025
Negative
- Total debt principal of $9.2B as of December 31, 2025
- Net cash provided by operating activities declined 10% YoY to $2,490M for 2025
- Promacta receipts down 38% in Q4 2025 due to U.S. generic competition
- Estimated interest paid guidance of $350M–$360M for 2026
Key Figures
Market Reality Check
Peers on Argus
RPRX was up 0.36% while key biotech peers like BNTX, GMAB, INCY and INSM showed declines; only SMMT was slightly positive, pointing to stock-specific strength rather than a sector-wide move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 05 | Q3 2025 earnings | Positive | +6.8% | Double-digit Q3 growth and raised 2025 Portfolio Receipts guidance. |
| Aug 06 | Q2 2025 earnings | Positive | -2.1% | Strong 20% Portfolio Receipts growth with higher full-year guidance. |
| May 08 | Q1 2025 earnings | Positive | +1.1% | 17% Portfolio Receipts growth, guidance raise, buybacks and dividend hike. |
| Feb 11 | Q4 2024 earnings | Positive | +1.7% | Strong 2024 growth, $2.8B capital deployment, and higher 2025 outlook. |
| Nov 06 | Q3 2024 earnings | Positive | -3.3% | 15% Portfolio Receipts growth and guidance raise despite later share weakness. |
Earnings releases are generally positive and often followed by modest gains, though there are notable instances of divergence where strong reports saw negative price reactions.
Over the last five earnings cycles from Nov 2024 through Nov 2025, Royalty Pharma consistently reported double‑digit Portfolio Receipts growth, frequent guidance raises, and sizable capital deployment and buybacks. Price reactions were mixed: strong upside on Q3 2025, smaller gains on other beats, and two quarters where solid results coincided with a selloff. Today’s Q4/FY 2025 report, with 16% Portfolio Receipts growth and 2026 guidance, extends this pattern of steady operational execution.
Historical Comparison
In the past year, RPRX’s earnings releases moved the stock an average of 0.84%. Today’s 0.36% change is smaller but directionally consistent with generally constructive reactions.
Earnings updates from late 2024 through 2025 show sustained double‑digit Portfolio Receipts growth, repeated guidance raises, and growing capital deployment and buybacks.
Market Pulse Summary
This announcement highlights another year of strong execution, with Q4 2025 Portfolio Receipts of $874M, full-year growth of 16%, and 2026 guidance of $3.275–$3.425B. Management emphasized substantial capital deployment of $2.6B, significant share repurchases, and a higher dividend. Historically, earnings updates have combined steady growth with active portfolio rotation, so investors may watch future receipts, cash generation, and pipeline catalysts for daraxonrasib, pelacarsen, and litifilimab.
Key Terms
Adjusted EBITDA financial
Portfolio Cash Flow financial
non-GAAP financial
Phase 3 medical
Biologics License Application (BLA) regulatory
Marketing Authorization Application regulatory
New Drug Application regulatory
accelerated approval regulatory
AI-generated analysis. Not financial advice.
- Portfolio Receipts of
$874 million in Q4 2025 and$3,254 million for FY 2025 - Portfolio Receipts growth of
18% in Q4 2025 and16% for FY 2025 - Net cash provided by operating activities of
$827 million in Q4 2025 and$2,490 million for FY 2025 - Full year 2026 guidance: Portfolio Receipts expected to be
$3,275 million to$3,425 million
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2025 and introduced full year 2026 guidance for Portfolio Receipts.
“We had one of the most remarkable years in Royalty Pharma’s history in 2025,” said Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board. “We grew Portfolio Receipts by
Strong double-digit growth in Royalty Receipts and Portfolio Receipts
- Royalty Receipts grew
17% to$856 million in the fourth quarter and13% to$3,127 million in 2025, primarily driven by Voranigo, Trelegy, Tremfya and the cystic fibrosis franchise. - Portfolio Receipts increased by
18% to$874 million in the fourth quarter and16% to$3,254 million in 2025.
Balanced capital allocation approach drives value creation
- Capital Deployment of
$2.6 billion ; added royalties on nine(8) therapies to portfolio in the year, including a ground-breaking partnership with Revolution Medicines for Phase 3 therapy daraxonrasib for pancreatic cancer. - Repurchased 37 million Class A ordinary shares for
$1.2 billion in 2025, including$75 million in the fourth quarter. - Increased quarterly dividend by
7% in the first quarter of 2026.
Positive clinical and regulatory updates across royalty portfolio in 2025
- FDA approvals of Cytokinetics' Myqorzo (formerly aficamten) in obstructive hypertrophic cardiomyopathy and Johnson & Johnson's Tremfya in Crohn's disease and ulcerative colitis.
- Positive Phase 3 results for Teva's TEV-'749 in schizophrenia, Gilead's Trodelvy in 1L metastatic triple negative breast cancer, Emalex's ecopipam in Tourette's syndrome and Pharvaris' deucrictibant in hereditary angioedema.
Financial guidance for full year 2026 (excludes contribution from future transactions)
- Royalty Pharma expects 2026 Portfolio Receipts to be between
$3,275 million and$3,425 million . - 2026 Portfolio Receipts guidance includes expected growth in Royalty Receipts of
3% to8% .
Financial & Liquidity Summary
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||
| (unaudited) | ||||||||
| ($ and shares in millions) | 2025 | 2024 | Change | 2025 | 2024 | Change | ||
| Portfolio Receipts | 874 | 742 | 3,254 | 2,801 | ||||
| Net cash provided by operating activities | 827 | 743 | 2,490 | 2,769 | (10)% | |||
| Adjusted EBITDA (non-GAAP)* | 816 | 669 | 2,966 | 2,565 | ||||
| Portfolio Cash Flow (non-GAAP)* | 815 | 678 | 2,724 | 2,452 | ||||
| Weighted average Class A ordinary shares outstanding - diluted | 556 | 589 | (6)% | 564 | 594 | (5)% | ||
*See “Liquidity and Capital Resources” section. Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures calculated in accordance with the credit agreement.
2026 Financial Outlook
Royalty Pharma has provided guidance for full year 2026, excluding new transactions and borrowings announced after the date of this release, as follows:
| Provided February 11, 2026 | |
| Portfolio Receipts | |
| Payments for operating and professional costs | |
| Interest paid |
Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. The above Portfolio Receipts guidance includes expected Royalty Receipts growth of
Royalty Pharma’s full year 2026 guidance reflects an estimated foreign exchange impact of approximately +
Payments for operating and professional costs in 2026 are expected to decrease as a percentage of Portfolio Receipts, compared to
Total interest paid is based on the semi-annual interest payment schedule of Royalty Pharma’s existing notes and the quarterly interest payment schedule for the term loan assumed as part of the internalization transaction. In 2026, Royalty Pharma anticipates interest paid to be approximately
Royalty Pharma today provides this guidance based on its most up-to-date view of its prospects. This guidance assumes no major unforeseen adverse events or changes in foreign exchange rates and excludes the contributions from transactions announced subsequent to the date of this press release.
Portfolio Receipts Highlights
| Three Months Ended December 31, | ||||||
| (unaudited) | ||||||
| ($ in millions) | 2025 | 2024 | Change | |||
| Products: | Marketers: | Therapeutic Area: | ||||
| Cystic fibrosis franchise | Vertex | Rare disease | 251 | 237 | ||
| Trelegy | GSK | Respiratory | 95 | 74 | ||
| Tysabri | Biogen | Neuroscience | 65 | 61 | ||
| Evrysdi | Roche | Rare disease | 64 | 56 | ||
| Tremfya | Johnson & Johnson | Immunology | 56 | 39 | ||
| Xtandi | Pfizer, Astellas | Oncology | 53 | 46 | ||
| Imbruvica | AbbVie, Johnson & Johnson | Oncology | 40 | 46 | (13)% | |
| Voranigo | Servier | Oncology | 39 | 5 | * | |
| Promacta | Novartis | Hematology | 27 | 44 | (38)% | |
| Cabometyx/Cometriq | Exelixis, Ipsen, Takeda | Oncology | 22 | 20 | ||
| Spinraza | Biogen | Rare disease | 14 | 15 | (4)% | |
| Erleada | Johnson & Johnson | Oncology | 13 | 11 | ||
| Trodelvy | Gilead | Oncology | 12 | 11 | ||
| Imdelltra | Amgen | Oncology | 10 | — | n/a | |
| Other products(6) | 96 | 67 | ||||
| Royalty Receipts | 856 | 729 | ||||
| Milestones and other contractual receipts | 18 | 13 | ||||
| Portfolio Receipts | 874 | 742 | 18% | |||
*Percentage change is not meaningful.
Amounts shown in the table may not add due to rounding. Results for full year 2025 and 2024 are shown in Table 5.
Royalty Receipts was
Portfolio Receipts was
Liquidity and Capital Resources
Royalty Pharma’s liquidity and capital resources are summarized below:
As of December 31, 2025, Royalty Pharma had cash and cash equivalents of
In 2025, Royalty Pharma paid a quarterly dividend of
In January 2025, Royalty Pharma announced a new share repurchase program under which it may repurchase up to
In January 2025, Royalty Pharma accelerated its return by selling the MorphoSys Development Funding Bonds for
Liquidity Summary
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||
| (unaudited) | ||||||||
| ($ in millions) | 2025 | 2024 | 2025 | 2024 | ||||
| Portfolio Receipts | 874 | 742 | 3,254 | 2,801 | ||||
| Payments for operating and professional costs | (58) | (72) | (288) | (236) | ||||
| Adjusted EBITDA (non-GAAP) | 816 | 669 | 2,966 | 2,565 | ||||
| Interest (paid)/received, net | (0) | 8 | (242) | (113) | ||||
| Portfolio Cash Flow (non-GAAP) | 815 | 678 | 2,724 | 2,452 | ||||
Amounts may not add due to rounding.
- Adjusted EBITDA (non-GAAP) was
$816 million in the fourth quarter of 2025. Adjusted EBITDA is calculated as Portfolio Receipts minus payments for operating and professional costs. - Portfolio Cash Flow (non-GAAP) was
$815 million in the fourth quarter of 2025. Portfolio Cash Flow is calculated as Adjusted EBITDA minus interest paid or received, net. This measure reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases, or utilized for other discretionary investments.
Refer to Table 4 for Royalty Pharma’s reconciliation of each non-GAAP measure to the most directly comparable GAAP financial measure, net cash provided by operating activities.
Capital Deployment reflects cash payments during the period for new and previously announced transactions. Capital Deployment was
The table below details Capital Deployment by category:
Capital Deployment
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||
| (unaudited) | ||||||||
| ($ in millions) | 2025 | 2024 | 2025 | 2024 | ||||
| Purchases of available for sale debt securities | (100) | — | (175) | (150) | ||||
| Acquisitions of financial royalty assets | (734) | (496) | (1,698) | (2,506) | ||||
| Acquisitions of other financial assets | — | — | — | (18) | ||||
| Development-stage funding payments | (51) | (1) | (452) | (2) | ||||
| Milestone payments | (3) | (25) | (271) | (75) | ||||
| Investments in equity method investees | — | — | — | (11) | ||||
| Contributions from legacy non-controlling interests - R&D | — | 0 | 0 | 1 | ||||
| Capital Deployment | (887) | (522) | (2,596) | (2,761) | ||||
Amounts may not add due to rounding.
Royalty Transactions
During 2025, Royalty Pharma announced new transactions of up to
Recent transactions include:
- In January 2026, Royalty Pharma announced a funding agreement with Teva Pharmaceuticals for TEV-’408 for up to
$500 million . The agreement includes$75 million to co-fund a Phase 2b study for vitiligo targeted for 2026. Based on the future results from the Phase 2b study in vitiligo, Royalty Pharma will have an option to provide an additional$425 million to co-fund the Phase 3 development program. - In December 2025, Royalty Pharma acquired the remaining royalties on Roche's Evrysdi for the treatment of spinal muscular atrophy from PTC Therapeutics for an upfront payment of
$240 million and up to$60 million in sales-based milestones. - In December 2025, Royalty Pharma acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an undisclosed party for up to
$315 million , including an upfront payment of$155 million . Neladalkib and zidesamtinib are next-generation tyrosine kinase inhibitors (TKIs). Neladalkib is in development for patients with anaplastic lymphoma kinase (ALK) mutation-positive non-small cell lung cancer (NSCLC) and zidesamtinib is in development for ROS proto-oncogene 1 (ROS1) mutation-positive NSCLC. - In December 2025, Royalty Pharma announced a transaction to acquire a royalty interest in Denali Therapeutics’ tividenofusp alfa for up to
$275 million . Tividenofusp alfa is Denali’s lead investigational TransportVehicle-enabled enzyme replacement therapy for the treatment of mucopolysaccharidosis type II (MPS II, or Hunter syndrome). Royalty Pharma will make a$200 million payment contingent on U.S. Food and Drug Administration (FDA) accelerated approval and a$75 million payment on European Medicines Agency (EMA) approval if achieved by December 31, 2029.
The information in this section should be read together with Royalty Pharma’s reports and documents filed with the SEC at www.sec.gov and the reader is also encouraged to review all other press releases and information available in the Investors section of Royalty Pharma’s website at www.royaltypharma.com.
Key Developments Relating to the Portfolio
The key developments related to Royalty Pharma’s royalty interests are discussed below based on disclosures from the marketers of the products.
| Spinraza | In January 2026, Biogen announced that the European Commission granted marketing authorization for a high dose regimen of Spinraza for spinal muscular atrophy. |
| pelabresib | In January 2026, Novartis announced plans to submit a European Union regulatory filing for pelabresib in 2026, and that it would begin a new Phase 3 study in 2026 in the United States, Canada and Japan. |
| obexelimab | In January 2026, Zenas BioPharma (Zenas) announced positive results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-related disease (lgG4-RD), which met the primary endpoint demonstrating a clinically meaningful and highly statistically significant reduction in risk of lgG4-RD flare. Zenas anticipates submitting a Biologics License Application (BLA) in Q2 2026 and a Marketing Authorization Application to the EMA in the second half of 2026. In October 2025, Zenas announced positive results from the Phase 2 trial of obexelimab in relapsing multiple sclerosis, which demonstrated a highly statistically significant |
| Myqorzo (aficamten) | In December 2025, Cytokinetics announced the FDA approval of Myqorzo for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy. |
| TEV-'749 | In December 2025, Teva Pharmaceuticals submitted a New Drug Application to the FDA for olanzapine LAI for the treatment of schizophrenia in adults. |
| deucrictibant | In December 2025, Pharvaris announced positive topline data from the RAPIDe-3 pivotal Phase 3 study, which met its primary endpoint and all secondary efficacy endpoints with statistical significance. The data will serve as the basis for marketing authorization applications expected to be filed in first half of 2026. |
| Cobenfy | In December 2025, Bristol Myers Squibb announced that it will enroll additional patients in the Phase 3 ADEPT-2 study of Cobenfy in psychosis associated with Alzheimer’s disease. Following consultation with the FDA and a review by the independent Data Monitoring Committee, the study will continue as planned with results expected by the end of 2026. |
| Imdelltra | In November 2025, Amgen announced that the FDA granted full approval to Imdelltra for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy, converting Imdelltra’s prior accelerated approval into a full approval. |
| Tysabri | In November 2025, Sandoz announced the U.S. launch of Tyruko, the first and only FDA-approved biosimilar to Biogen’s Tysabri. |
| Trodelvy | In November 2025, Gilead announced the Phase 3 ASCENT-07 study investigating Trodelvy as a first-line (1L) treatment for HR+/HER2-negative metastatic breast cancer patients did not meet the primary endpoint of progression-free survival. Overall survival is a key secondary endpoint and was not mature at the time of the primary analysis. In October 2025, Gilead announced that based on the positive Phase 3 updates from ASCENT-03 and ASCENT-04, it has submitted two supplemental BLAs for Trodelvy in 1L metastatic triple-negative breast cancer and expects regulatory decisions in 2026. |
| daraxonrasib | In October 2025, Revolution Medicines announced that the FDA granted a non-transferrable voucher for daraxonrasib under the Commissioner’s National Priority Voucher pilot program, which accelerates target review times to 1-2 months versus 6+ months. |
| litifilimab | In October 2025, Biogen announced that both litifilimab Phase 3 studies for systemic lupus erythematosus are fully enrolled with expected data readout for both studies accelerated to the second half of 2026. |
Financial Results Call
Royalty Pharma will host a conference call and simultaneous webcast to discuss its fourth quarter and full year 2025 results today at 8:00 a.m., Eastern Time. Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Biogen’s Tysabri and Spinraza, Roche’s Evrysdi, Astellas and Pfizer’s Xtandi, Johnson & Johnson’s Tremfya, AbbVie and Johnson & Johnson’s Imbruvica, Servier’s Voranigo, Gilead’s Trodelvy, Amgen’s Imdelltra and Alnylam’s Amvuttra, among others, and 20 development-stage product candidates.
Forward-Looking Statements
The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.
This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities, market growth and plans for capital deployment, plus the benefits of the internalization transaction, including expected accretion, enhanced alignment with shareholders, increased investment returns, expectations regarding management continuity, transparency and governance, and the benefits of simplification to its structure. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.
For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission ("SEC") by visiting EDGAR on the SEC's website at www.sec.gov.
Portfolio Receipts
Portfolio Receipts is a key performance metric that represents Royalty Pharma’s ability to generate cash from Royalty Pharma’s portfolio investments, the primary source of capital that is deployed to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. Royalty Receipts includes variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma.
Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include royalty receipts and milestones and other contractual receipts that were received on an accelerated basis under the terms of the agreement governing the receipt or payment. Portfolio Receipts also does not include proceeds from equity securities or proceeds from purchases and sales of marketable securities, both of which are not central to Royalty Pharma’s fundamental business strategy, and excludes the
Portfolio Receipts is calculated as the sum of the following line items from Royalty Pharma’s GAAP consolidated statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees less Distributions to legacy non-controlling interests - Portfolio Receipts, which represent contractual distributions of Royalty Receipts, milestones and other contractual receipts to the Legacy Investors Partnerships.
Use of Non-GAAP Measures
Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures that exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. Management believes that Adjusted EBITDA and Portfolio Cash Flow are important non-GAAP measures used to analyze liquidity because they are key components of certain material covenants contained within Royalty Pharma’s credit agreement. Royalty Pharma cautions readers that amounts presented in accordance with the definitions of Adjusted EBITDA and Portfolio Cash Flow may not be the same as similar measures used by other companies or analysts. These non-GAAP liquidity measures have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of Royalty Pharma’s results as reported under GAAP.
The definitions of Adjusted EBITDA and Portfolio Cash Flow used by Royalty Pharma are the same as the definitions in the credit agreement. Noncompliance with the interest coverage ratio, leverage ratio and Portfolio Cash Flow ratio covenants under the credit agreement could result in lenders requiring the company to immediately repay all amounts borrowed. If Royalty Pharma cannot satisfy these covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA and Portfolio Cash Flow are critical to the assessment of Royalty Pharma’s liquidity.
Adjusted EBITDA and Portfolio Cash Flow are used by management as key liquidity measures in the evaluation of the company’s ability to generate cash from operations. Management uses Adjusted EBITDA and Portfolio Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, debt repayments, dividends and other discretionary investments. Further, these non-GAAP liquidity measures help management, the audit committee and investors evaluate the company’s ability to generate liquidity from operating activities.
The company has provided reconciliations of these non-GAAP liquidity measures to the most directly comparable GAAP financial measure, being net cash provided by operating activities in Table 4.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
| Royalty Pharma plc Condensed Consolidated Statements of Operations (unaudited) Table 1 | ||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||
| ($ in millions) | 2025 | 2024 | 2025 | 2024 | ||||
| Income and other revenues | ||||||||
| Income from financial royalty assets | 592 | 562 | 2,261 | 2,149 | ||||
| Other royalty income and revenues | 30 | 32 | 117 | 114 | ||||
| Total income and other revenues | 622 | 594 | 2,378 | 2,264 | ||||
| Operating expense/(income) | ||||||||
| Provision for changes in expected cash flows from financial royalty assets | 23 | 164 | (296) | 732 | ||||
| Provision for credit losses on unfunded commitments | (4) | — | 89 | — | ||||
| Research and development funding expense | 51 | 1 | 452 | 2 | ||||
| General and administrative expenses (includes 126, 291, 1, and 3 of share-based compensation expense for the three months and twelve months ended December 31, 2025 and 2024, respectively) | 164 | 68 | 573 | 237 | ||||
| Total operating expense, net | 234 | 232 | 819 | 971 | ||||
| Operating income | 388 | 362 | 1,560 | 1,292 | ||||
| Other (income)/expense | ||||||||
| Equity in earnings of equity method investees | (4) | (32) | (29) | (30) | ||||
| Interest expense | 94 | 66 | 308 | 226 | ||||
| Other income, net | (58) | (7) | (43) | (234) | ||||
| Total other expense/(income), net | 32 | 27 | 235 | (38) | ||||
| Consolidated net income before tax | 356 | 334 | 1,324 | 1,331 | ||||
| Income tax expense | — | — | — | — | ||||
| Consolidated net income | 356 | 334 | 1,324 | 1,331 | ||||
| Net income attributable to non-controlling interests | 142 | 126 | 553 | 472 | ||||
| Net income attributable to Royalty Pharma plc | 214 | 208 | 771 | 859 | ||||
Amounts may not add due to rounding.
| Royalty Pharma plc Selected Balance Sheet Data (unaudited) Table 2 | ||
| ($ in millions) | As of December 31, 2025 | As of December 31, 2024 |
| Cash and cash equivalents | 619 | 929 |
| Total current and non-current financial royalty assets, net | 17,063 | 15,911 |
| Total assets | 19,621 | 18,223 |
| Current portion of long-term debt | 380 | 998 |
| Long-term debt, net of current portion | 8,571 | 6,615 |
| Total liabilities | 9,906 | 7,880 |
| Total shareholders’ equity | 9,715 | 10,342 |
| Royalty Pharma plc Consolidated Statements of Cash Flows (unaudited) Table 3 | ||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||
| ($ in millions) | 2025 | 2024 | 2025 | 2024 | ||||
| Cash flows from operating activities: | ||||||||
| Cash collections from financial royalty assets | 916 | 777 | 3,355 | 2,983 | ||||
| Cash collections from intangible royalty assets | 0 | 0 | 1 | 15 | ||||
| Other royalty cash collections | 29 | 30 | 114 | 109 | ||||
| Distributions from equity method investees | — | — | 13 | 13 | ||||
| Interest received | 6 | 9 | 34 | 46 | ||||
| Development-stage funding payments | (51) | (1) | (452) | (2) | ||||
| Payments for operating and professional costs | (58) | (72) | (288) | (236) | ||||
| Payments for Employee EPAs | (9) | — | (11) | — | ||||
| Interest paid | (7) | (1) | (276) | (160) | ||||
| Net cash provided by operating activities | 827 | 743 | 2,490 | 2,769 | ||||
| Cash flows from investing activities: | ||||||||
| Acquisition of businesses, net of cash acquired | — | — | (74) | — | ||||
| Distributions from equity method investees | 5 | 3 | 105 | 24 | ||||
| Investments in equity method investees | — | — | — | (11) | ||||
| Purchases of equity securities | (54) | — | (58) | (63) | ||||
| Proceeds from equity securities | 35 | — | 35 | 99 | ||||
| Purchases of available for sale debt securities | (100) | — | (175) | (150) | ||||
| Proceeds from available for sale debt securities | 3 | 13 | 21 | 20 | ||||
| Proceeds from sales of available for sale debt securities | — | — | 511 | — | ||||
| Acquisitions of financial royalty assets | (734) | (496) | (1,698) | (2,506) | ||||
| Acquisitions of other financial assets | — | — | — | (18) | ||||
| Milestone payments | (3) | (25) | (271) | (75) | ||||
| Other | — | — | (9) | 2 | ||||
| Net cash used in investing activities | (848) | (506) | (1,614) | (2,678) | ||||
| Cash flows from financing activities: | ||||||||
| Distributions to legacy non-controlling interests - Portfolio Receipts | (79) | (81) | (355) | (362) | ||||
| Distributions to continuing non-controlling interests | (41) | (31) | (167) | (125) | ||||
| Dividends to shareholders | (94) | (94) | (378) | (376) | ||||
| Repurchases of Class A ordinary shares | (81) | (53) | (1,227) | (230) | ||||
| Contributions from legacy non-controlling interests - R&D | — | 0 | 0 | 1 | ||||
| Contributions from non-controlling interests - other | — | 1 | 6 | 4 | ||||
| Proceeds from revolving credit facility | — | — | 1,275 | — | ||||
| Repayment of revolving credit facility | — | — | (1,275) | — | ||||
| Repayment of long-term debt | — | — | (1,000) | — | ||||
| Proceeds from issuance of long-term debt, net of discount | — | — | 1,954 | 1,471 | ||||
| Debt issuance costs and other | (3) | 0 | (17) | (13) | ||||
| Other | (2) | 0 | (2) | (9) | ||||
| Net cash (used in)/provided by financing activities | (300) | (257) | (1,186) | 361 | ||||
| Net change in cash and cash equivalents | (320) | (20) | (310) | 452 | ||||
| Cash and cash equivalents, beginning of period | 939 | 950 | 929 | 477 | ||||
| Cash and cash equivalents, end of period | 619 | 929 | 619 | 929 | ||||
EPAs: Equity Performance Awards. Amounts may not add due to rounding.
| Royalty Pharma plc GAAP to Non-GAAP Reconciliation (unaudited) Table 4 | ||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||
| ($ in millions) | 2025 | 2024 | 2025 | 2024 | ||||
| Net cash provided by operating activities (GAAP) | 827 | 743 | 2,490 | 2,769 | ||||
| Adjustments: | ||||||||
| Proceeds from available for sale debt securities(7) | 3 | 13 | 21 | 20 | ||||
| Distributions from equity method investees(7) | 5 | 3 | 105 | 24 | ||||
| Interest paid/(received), net(7) | 0 | (8) | 242 | 113 | ||||
| Development-stage funding payments | 51 | 1 | 452 | 2 | ||||
| Distributions to legacy non-controlling interests - Portfolio Receipts(7) | (79) | (81) | (355) | (362) | ||||
| Payments for Employee EPAs | 9 | — | 11 | — | ||||
| Adjusted EBITDA (non-GAAP) | 816 | 669 | 2,966 | 2,565 | ||||
| Interest (paid)/received, net(7) | (0) | 8 | (242) | (113) | ||||
| Portfolio Cash Flow (non-GAAP) | 815 | 678 | 2,724 | 2,452 | ||||
EPAs: Equity Performance Awards. Amounts may not add due to rounding.
| Royalty Pharma plc Fourth Quarter and Full Year Portfolio Receipts Highlights (unaudited) Table 5 | ||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||
| ($ in millions) | 2025 | 2024 | Change | 2025 | 2024 | Change |
| Products: | ||||||
| Cystic fibrosis franchise | 251 | 237 | 917 | 857 | ||
| Trelegy | 95 | 74 | 332 | 284 | ||
| Tysabri | 65 | 61 | 250 | 262 | (5)% | |
| Evrysdi | 64 | 56 | 202 | 174 | ||
| Xtandi | 53 | 46 | 197 | 169 | ||
| Tremfya | 56 | 39 | 178 | 140 | ||
| Imbruvica | 40 | 46 | (13)% | 170 | 191 | (11)% |
| Promacta | 27 | 44 | (38)% | 142 | 158 | (11)% |
| Voranigo | 39 | 5 | * | 118 | 5 | * |
| Cabometyx/Cometriq | 22 | 20 | 85 | 73 | ||
| Spinraza | 14 | 15 | (4)% | 52 | 45 | |
| Trodelvy | 12 | 11 | 47 | 43 | ||
| Erleada | 13 | 11 | 46 | 39 | ||
| Imdelltra | 10 | — | n/a | 10 | — | n/a |
| Other products(6) | 96 | 67 | 381 | 333 | ||
| Royalty Receipts | 856 | 729 | 3,127 | 2,771 | ||
| Milestones and other contractual receipts | 18 | 13 | 128 | 31 | ||
| Portfolio Receipts | 874 | 742 | 18% | 3,254 | 2,801 | 16% |
*Percentage change is not meaningful.
Amounts may not add due to rounding.
| Royalty Pharma plc Description of Approved Indications for Select Portfolio Therapies Table 6 | |
| Cystic fibrosis franchise | Cystic fibrosis |
| Trelegy | Chronic obstructive pulmonary disease and asthma |
| Tysabri | Relapsing forms of multiple sclerosis |
| Evrysdi | Spinal muscular atrophy |
| Tremfya | Plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease |
| Xtandi | Prostate cancer |
| Imbruvica | Hematological malignancies and chronic graft versus host disease |
| Voranigo | Low-grade glioma |
| Promacta | Chronic immune thrombocytopenia purpura and aplastic anemia |
| Cabometyx/Cometriq | Kidney, liver and thyroid cancer |
| Spinraza | Spinal muscular atrophy |
| Erleada | Prostate cancer |
| Trodelvy | Breast cancer |
| Imdelltra | Small cell lung cancer |
Notes
| (1) | Portfolio Receipts is defined above in the section entitled “Portfolio Receipts.” |
| (2) | Adjusted EBITDA is defined under the credit agreement as Portfolio Receipts minus payments for operating and professional costs. Operating and professional costs reflect Payments for operating and professional costs from the GAAP consolidated statements of cash flows. See GAAP to Non-GAAP reconciliation in Table 4. |
| (3) | Portfolio Cash Flow is defined under the credit agreement as Adjusted EBITDA minus interest paid or received, net. See GAAP to Non-GAAP reconciliation in Table 4. Portfolio Cash Flow reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases or utilized for other discretionary investments. |
| (4) | Capital Deployment is calculated as the summation of the following line items from Royalty Pharma’s GAAP consolidated statements of cash flows: Investments in equity method investees, Purchases of available for sale debt securities, Acquisitions of financial royalty assets, Acquisitions of other financial assets, Milestone payments, Development-stage funding payments less Contributions from legacy non-controlling interests - R&D. |
| (5) | The term loan that Royalty Pharma assumed as part of the Internalization has a Secured Overnight Financing Rate (SOFR) based variable interest rate. Royalty Pharma estimated the related interest payment for 2026 based on the forward curve as of February 5, 2026. |
| (6) | Other products primarily include Royalty Receipts on the following products: Crysvita, Emgality, Entyvio, Farxiga/Onglyza, IDHIFA, Nesina, Nurtec ODT, Orladeyo, Prevymis, Soliqua and distributions from the Legacy SLP Interest, which is presented as Distributions from equity method investees on the GAAP consolidated statements of cash flows. |
| (7) | The table below shows the line item for each adjustment and the direct location for such line item on the GAAP consolidated statements of cash flows. |
| Reconciling Adjustment | Statements of Cash Flows Classification |
| Interest (paid)/received, net | Operating activities (Interest paid less Interest received) |
| Distributions from equity method investees | Investing activities |
| Proceeds from available for sale debt securities | Investing activities |
| Distributions to legacy non-controlling interests - Portfolio Receipts | Financing activities |
| (8) | Includes royalty interest on Denali’s tividenofusp alfa which is contingent on its FDA accelerated approval. |
FAQ
What did Royalty Pharma (RPRX) report for Q4 2025 Portfolio Receipts?
What full‑year 2026 Portfolio Receipts guidance did RPRX provide on Feb 11, 2026?
How much did Royalty Pharma (RPRX) deploy and repurchase in 2025 and what was the dividend change?
How did Royalty Pharma’s operating cash flow and adjusted EBITDA perform in 2025?
What material transaction activity did RPRX announce in late 2025 and January 2026?
What are the key liquidity figures for Royalty Pharma (RPRX) at Dec 31, 2025?
